Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib.
about
Mediator of ERBB2-driven cell motility (MEMO) promotes extranuclear estrogen receptor signaling involving the growth factor receptors IGF1R and ERBB2Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancerDistinct splice variants and pathway enrichment in the cell-line models of aggressive human breast cancer subtypesLapatinib: an oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer.Effects of lapatinib and trastuzumab on vascular endothelial growth factor in experimental corneal neovascularization.
P2860
Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Management of ErbB2-positive b ...... inical studies with lapatinib.
@ast
Management of ErbB2-positive b ...... inical studies with lapatinib.
@en
Management of ErbB2-positive b ...... inical studies with lapatinib.
@nl
type
label
Management of ErbB2-positive b ...... inical studies with lapatinib.
@ast
Management of ErbB2-positive b ...... inical studies with lapatinib.
@en
Management of ErbB2-positive b ...... inical studies with lapatinib.
@nl
prefLabel
Management of ErbB2-positive b ...... inical studies with lapatinib.
@ast
Management of ErbB2-positive b ...... inical studies with lapatinib.
@en
Management of ErbB2-positive b ...... inical studies with lapatinib.
@nl
P2093
P2860
P921
P356
P1476
Management of ErbB2-positive b ...... inical studies with lapatinib.
@en
P2093
Arlene Chan
Brunilde Gril
Charles Vogel
Hanlim Moon
Junichi Kurebayashi
Sung-Bae Kim
Yen-Shen Lu
P275
P2860
P304
P356
10.1093/JJCO/HYQ084
P5008
P577
2010-06-11T00:00:00Z
2010-11-01T00:00:00Z